Tag Directory

Companies & Orgs People Topics


Companies, Departments & Organizations


Tag Coverage Started Last Seen Stories Count
Back to Top


People


Tag Coverage Started Last Seen Stories Count
Back to Top


Topics


Tag Coverage Started Last Seen Stories Count
Animal HealthFeb. 28, 2026Feb. 28, 20261
AutismNov. 20, 2025Feb. 16, 20263
Avian InfluenzaFeb. 28, 2026Feb. 28, 20261
Behavioral HealthFeb. 27, 2026Mar. 7, 20266
BiotechNov. 8, 2025Mar. 9, 202685
Cancer ResearchMar. 7, 2026Mar. 9, 20262
CDCNov. 20, 2025Mar. 2, 202622
Corporate TakeoverNov. 8, 2025Mar. 9, 202618
Digital HealthJan. 17, 2026Mar. 7, 202628
Drug DevelopmentNov. 8, 2025Mar. 9, 202684
Drug PricingNov. 7, 2025Mar. 7, 202619
Eli LillyNov. 7, 2025Mar. 7, 202610
FDANov. 12, 2025Mar. 7, 202647
Food SafetyJan. 10, 2026Feb. 14, 20265
Government PolicyNov. 7, 2025Mar. 10, 2026111
HealthcareNov. 7, 2025Mar. 10, 2026261
Healthcare FinanceFeb. 27, 2026Mar. 10, 202623
Hospital OperationsFeb. 27, 2026Mar. 10, 20269
Infant HealthJan. 10, 2026Mar. 9, 202616
Infectious DiseaseFeb. 28, 2026Mar. 7, 20265
Medical DevicesFeb. 14, 2026Mar. 7, 202611
Mergers and AcquisitionsNov. 8, 2025Mar. 9, 202621
NoneNov. 8, 2025Mar. 7, 202611
Novo NordiskNov. 7, 2025Mar. 6, 202613
ObesityNov. 7, 2025Mar. 7, 202621
OncologyFeb. 14, 2026Mar. 9, 202622
Pancreatic CancerFeb. 14, 2026Mar. 7, 20262
PfizerNov. 8, 2025Nov. 10, 20252
PharmaceuticalsNov. 7, 2025Mar. 9, 2026108
Product RecallJan. 10, 2026Jan. 10, 20261
Public HealthNov. 7, 2025Mar. 10, 2026202
Research FundingMar. 7, 2026Mar. 9, 20262
Trump AdministrationNov. 7, 2025Jan. 23, 20264
Vaccine SafetyNov. 20, 2025Mar. 6, 202622
Weight LossNov. 7, 2025Mar. 7, 202619
WildlifeFeb. 28, 2026Feb. 28, 20261
Zoonotic DiseaseFeb. 28, 2026Feb. 28, 20261
Back to Top


More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.